With a new price target of $32.50, BSEM could be one of the most undervalued biotech stocks right now
 | A Message on Behalf of Biostem Technologies | With a new price target of $32.50, $BSEM is one of the most undervalued biotech stocks right now! |  | Zacks Small Cap Research has increased its price target yet again to $32.50 from $24.25 after a stellar Q3 performance! Could another price target upgrade be on the way? What Did Zacks Have to Say About BSEM's Q3 Performance?
"As a result of the quarterly results and impressive continued growth, as well as the solid management execution, we are boosting our price target to $32.50 per share. These announcements further our belief that BioStem is a company worth paying attention to and that BSEM has solid upside potential. Additionally, we continue to be impressed with the leadership of BioStem, headed by CEO Jason Matuszewski, which has remained confident in its products and science, while also focusing on getting the improved solution out to patients and accelerating commercial growth—as is demonstrated by continuing to test its proven technology and expand the availability of the company's treatments."
With Q3 Results on the Way, Could Another Price Target Increase be Imminent?
AND ON ANOTHER EXCITING FRONT, A NASDAQ LISTING COULD BE AROUND THE CORNER FOR THE COMPANY!
BSEM just announced that it has filed with the SEC to register its shares pursuant to the Securities Exchange Act of 1934, which is an important step in its plan to uplist to the Nasdaq stock exchange.
BSEM on the NASDAQ would open up the stock to new investors, especially on the institutional front | | Show Me The Stock Chart! | | | This message is a paid advertisement for Biostem Technologies from Sideways Frequency. Schaeffer's Investment Research Inc. receives a fixed fee for each subscriber that clicks on a link in this email. Other than the compensation received for this advertisement sent to subscribers, Schaeffer's Investment Research Inc. and its principals are not affiliated with Biostem Technologies. Schaeffer's Investment Research Inc. and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither Schaeffer's Investment Research Inc. nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Schaeffer's Investment Research Inc. to buy or sell any security. Schaeffer's Investment Research Inc. has not evaluated the accuracy of any claims made in this advertisement. Schaeffer's Investment Research Inc. recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Biostem Technologies on Biostem Technologies website for additional information. |
|
|
|
|
No comments:
Post a Comment